Celgene Corporation (CELG): Has Multiple Myeloma Met its Match?

Onyx Pharmaceuticals, Inc. (NASDAQ:ONXX) top line is projected to be $1.23 billion, representing a massive 50% annualized growth rate. Net income should move into positive territory to around $300 million by 2015. It earns 2 out of 5 stars and is more of a speculative bet.

Johnson & Johnson’s top line growth should range between 2.5% to 5% annually through 2015, with revenue increasing from $67.22 billion to $76.68 billion. Its bottom line is expected to grow between 17.5% to 20%, with net income rising from $10.85 billion to $17.85 billion. The company presently holds a price to earnings ratio of 24.47, and pays out a dividend yielding 2.93%. Overall, it earns 4 out of 5 Caps stars and is a solid investment that always seems to be overpriced.

Foolish bottom line

While recent news from Celgene Corporation (NASDAQ:CELG) is encouraging for investors and patients, it’s also likely to result in accelerated growth in international markets. Despite the exposure of the other companies to the treatment of multiple myeloma, none of the drugs they offer make up a large enough piece of their revenue to be considered crucial. Ultimately, this is a major breakthrough for Celgene and should fuel growth for the foreseeable future.

The article Has Multiple Myeloma Met its Match? originally appeared on Fool.com.

Copyright © 1995 – 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.